ROLE OF ANGIOTENSIN II RECEPTOR TYPE 2 IN PREDICTING BIOCHEMICAL RECURRENCE IN THE TREATMENT OF PROSTATE CANCER


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Aim. To identify markers for predicting aggressive forms of prostate cancer. Materials and methods. The study retrospectively evaluated expression of angiotensin II type 2 receptors (AT2-R) in prostate needle biopsy tissue from patients with and without biochemical recurrence after combined hormone and radiation therapy. Results. The study findings showed that low expression of AT2-R in prostate tissue was associated with a high risk of biochemical recurrence. The data on the nature of AT2-R expression in prostate tissue of prostate cancer patients may be considered as a tool for predicting biochemical recurrence after combined hormone and radiation therapy. The test has a sensitivity of 87.5% and specificity of 85.71%.

Full Text

Restricted Access

About the authors

M. B Chibichyan

nstitute of Arid Zones of Southern Scientific Center of RAS; Rostov State Medical University

Email: michel_dept@mail.ru
Ph.D., Associate Professor at Department of Urology and Human Reproductive Health with Course of Pediatric Urology-Andrology, Faculty of AT and PRS Rostov-on-Don

M. I Kogan

nstitute of Arid Zones of Southern Scientific Center of RAS; Rostov State Medical University

Email: dept_kogan@mail.ru
Rostov-on-Don

E. A Chernogubova

nstitute of Arid Zones of Southern Scientific Center of RAS; Rostov State Medical University

Email: eachernogubova@mail.ru
Rostov-on-Don

I. A Pavlenko

Rostov Region Pathology and Autopsy Bureau

Email: pavlenko.ir@gmail.com
Rostov-on-Don

D. G Matishov

nstitute of Arid Zones of Southern Scientific Center of RAS

Rostov-on-Don

References

  1. Siegel R., Miller K.D, Jemal A. Cancer Statistics, 2015. C.A. Cancer J. Clin. 2015;65(1):5-29. doi: 10.3322/caac.21254
  2. Каприн А.Д., Старинский В.В., Петрова Г.В. Злокачественные новообразования в России в 2014 году (заболеваемость и смертность). М.: МНИОИ им. П.А. Герцена -филиал ФГБУ НМИРЦ Минздрава России, 2016. 250 с
  3. Архипова О.Е., Черногубова Е.А., Лихтанская Н.В., Кулыгин В.В., Шевердяев И.В., Куролап С.А., Епринцев С.А., Тарасов В.А., Матишов Д.Г. (ред.) Пространственно-временной анализ встречаемости онкологических заболеваний как индикатора медико-экологической безопасности. Ростов-на-Дону: Изд-во Южного научного центра РАН; 2014. 224 с
  4. Otero J.R., Gomez B.G., Juanatey F.C., Touijer K.A. Prostate cancer biomarkers: An update. Urol Oncol. 2014;32(3): 252-260. doi: 10.1016/j.urolonc.2013.09.017.
  5. Filson C.P., Marks L.S., Litwin M.S. Expectant management for men with early stage prostate cancer. Cancer J Clin. 2015;65(4):265-282. doi: 10.3322/caac.21278.
  6. Bernstein K.E., Ong F.S., Blackwell W.L., Shah K.H., Giani J.F., Gonzalez-Villalobos R.A., Shen X.Z., Fuchs S., Touyz R.M. A modern understanding of the traditional and nontraditional biological functions of angiotensin-converting enzyme. Pharmacol Rev. 2012;65(1):1 -46. doi: 10.1124/pr.112.006809.
  7. George A.J., Thomas W.G., Hannan R.D. The renin-angiotensin system and cancer: old dog, new tricks. Nat Rev Cancer. 2010;10(11):745-759. doi: 10.1038/nrc2945.
  8. Verhoest G., Dolley-Hitze T., Jouan F., Bensalah K., Arlot-Bonnemains Y., Dugay F., Belaud-Rotureau M.A., Rioux-Leclercq N., Vigneau C. Renin-angiotensin system and urological cancers. Progrès en urologie. 2014;24:73-79. doi: 10.1016/j.purol.2013.09.010.
  9. Коган М.И., Черногубова Е.А., Чибичян М.Б., Мационис А.Э., Повилайтите П.Э., Матишов Д.Г. Роль калликреин-кининовой и ренин-ангиотензиновой систем в патогенезе рака предстательной железы. Урология. 2015;3:50-54
  10. Uemura H., Kubota Y. Application of angiotensin II receptor blocker in prostate cancer. Nippon. Rinsho. 2009;67(4):807-811.
  11. Deshayes F., Nahmias C. Angiotensin II receptors: a new role in cancer? Trends Endocrinol. Metabol. 2005; 16(7): 293-299.
  12. Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Molecular Endocrinology. 2006;20:953-970. DOI:10.1210/ me.2004-0536.
  13. Kaschina E., Unger T. Angiotensin AT1/AT2 receptors: regulation, signalling and function. Blood Press. 2003;12(2):70-88.
  14. Кугаевская Е.В., Тимошенко О.С., Соловьева Н.И. Ангиотензин превращающий фермент: антигенные свойства доменов, роль в метаболизме пептида бета-амилоида и опухолевой прогрессии. Биомедицинская химия. 2015 ; 61 (3) : 301-311
  15. Carbajo-Lozoya J., Lutz S., Feng Y., Kroll J., Hammes H.P., Wieland T. Angiotensin II modulates VEGF-driven angiogenesis by opposing effects of type 1 and type 2 receptor stimulation in the microvascular endothelium. Cell Signal. 2012;24:1261-1269. DOI: 10.1016/j. cellsig.2012.02.005.
  16. Wegman-Ostrosky T., Soto-Reyes E., Vidal-Millan S., Sanchez-Corona J. The renin-angiotensin system meets the hallmarks of cancer. J Renin Angiotensin Aldosterone Syst. 2015;16(2):227-233. doi: 10.1177/1470320313496858.
  17. ГОСТР 52379-2005 Национальный стандарт РФ «Надлежащая клиническая практика» (Good Clinical Practice; GCP), (утвержден приказом Федерального агентства по техническому регулированию и метрологии от 27 сентября 2005 г. N 232-ст
  18. Коган М.И., Лоран О.Б., Петров С.Б. Радикальная хирургия рака предстательной железы. М.: Гэотар-Медиа. 2006; 392 с
  19. ASTRO American Society for Therapeutic Radiology and Oncology Consensus Panel. Consensus statement: guidelines for PSA following radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. 1997;37(5):1035-1041.
  20. Roach M. 3rd, Hanks G., Thames H. Jr., Schellhammer P., Shipley W.U., Sokol G.H., Sandler H. Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int. J. Radiat. Biol. Phys. 2006; 65(4):965-974.
  21. Dabbs D.J. Diagnostic Immunohistochemistry. 2nd edit. Philadelphia, Churchill Livingstone: Elsevier; 2006: 828.
  22. Чибичян М.Б., Мационис A., Повилайтите П.Э., Коган М.И. Роль рецепторного аппарата калликреин-кининовой системы в пролиферативных процессах предстательной железы. Онкоурология. 2013;1:43-49
  23. Guimond M., Battista M., Nikjoutavabi F., Carmel M., Barres V., Doueik A.A., Fazli L., Gleave M., Sabbagh R., Gallo-Payet N. Expression and role of the angiotensin II AT2 receptor in human prostate tissue: In search of a new therapeutic option for prostate cancer. Prostate. 2013;73(10):1057-1068. DOI: 10.1002/ pros.22653.
  24. Okwan-Duodu D., Landry J., Shen X.Z., Diaz R. Angiotensinconverting enzyme and the tumor microenvironment: mechanisms beyond angiogenesis. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2013;305:R 205-215. doi: 10.1152/ajpregu.00544.2012.
  25. Hunyady L., Catt K.J. Pleiotropic AT1 receptor signaling pathways mediating physiological and pathogenic actions of angiotensin II. Molecular Endocrinology. 2006;20:953-970. DOI: 10.1210/ me.2004-0536.
  26. Botelho F., Pina F., Silva P., Figueiredo G., Cruz F., Lunet N. Vascular Endothelial Growth Factor (VEGF) and Prostate Pathology. International Braz J. Urol. 2010;36(4):430-438. DOI: 10.1590/ S1677-55382010000400006.
  27. Pei N., Jie F., Luo J., Wan R., Zhang Y., Chen X., Liang Z., Du H., Li A., Chen B., Zhang Y., Sumners C., Li J., Gu W., Li H. Gene Expression Profiling Associated with Angiotensin II Type 2 Receptor-Induced Apoptosis in Human Prostate Cancer Cells. PLoS One. 2014;9(3):e92253. doi: 10.1371/journal.pone0092253.
  28. Li J., Luo J., Gu D., Jie F., Pei N., Li A., Chen X., Zhang Y., Du H., Chen B., Gu W., Sumners C., Li H. Adenovirus-Mediated Angiotensin II Type 2 Receptor Overexpression Inhibits Tumor Growth of Prostate Cancer In Vivo. J Cancer. 2016;7(2):184-191. doi: 10.7150/jca.12841.
  29. Коган М.И., Чибичян М.Б., Черногубова E.A. Молекулярные механизмы развития биохимического рецидива после простатэктомиии при раке предстательной железы. Урологические ведомости. 2015;5(1):18-19

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies